Search

Your search keyword '"Pretzell, Ina"' showing total 8 results
Start Over Author "Pretzell, Ina"
8 results on '"Pretzell, Ina"'

1. Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123)

Author

Witte, David, Pretzell, Ina, Reissig, Timm M, Stein, Alexander, Velthaus, Janna-Lisa, Alig, Annabel, Bohnenberger, Hanibal, Knödler, Maren, Kurreck, Annika, Sulzer, Sabrina, Beyer, Georg, Dorman, Klara, Fröhlich, Tabea, Hegenberg, Stefanie, Lugnier, Celine, Saborowski, Anna, Vogel, Arndt, Lange, Sebastian, Reichert, Maximilian, Flade, Franziska, Klaas, Lioba, Utpatel, Kirsten, Becker, Heiko, Bleckmann, Annalen, Wethmar, Klaus, Reinacher-Schick, Anke, and Westphalen, Christoph Benedikt

Published
2024
Full Text
View/download PDF

2. PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors

Author

Abu Sabbah, Tanja, Theurer, Sarah, Baba, Hideo Andreas, Lueong, Smiths, Rashidi-Alavijeh, Jassin, Hilser, Thomas, Zaun, Yasmin, Metzenmacher, Martin, Pogorzelski, Michael, Virchow, Isabel, Pretzell, Ina, Kostbade, Karina, Treckmann, Jürgen, Wiesweg, Marcel, Schuler, Martin, Kasper, Stefan, and Zaun, Gregor

Published
2024
Full Text
View/download PDF

5. What Do German Molecular Tumor Boards Recommend in Patients with PIK3CA-Mutated Tumors? Launch and First Results from the German Transsectoral Molecular Tumor Board Exchange Platform Deutschland.

Author

Pretzell, Ina, Desuki, Alexander, Bleckmann, Annalen, Loges, Sonja, Reinacher-Schick, Anke, Westphalen, C. Benedikt, and Lange, Sebastian

Subjects
*MEDICAL personnel, *MOLECULAR diagnosis, *CAREGIVERS, *CANCER patients, *CLINICAL trials
Abstract

Introduction: Comprehensive molecular tumor profiling is widely used in the management of patients with cancer. Molecular tumor boards devise treatment strategies based on testing results. In this setting, the Transsectoral Molecular Tumor Board exchange platform Deutschland (TEAM-D) aims to drive peer-to-peer exchange to connect experts in the field. Methods: During the first virtual TEAM-D meeting, participants from 16 German universities and 5 nonacademic institutions discussed five cases with PIK3CA hotspot mutations. Furthermore, an illustrative case vignette was presented. Results: Overall, German caregivers show restraint in administering off-label PIK3CA inhibitor and favor clinical trials in this setting. Conclusion: In the setting of precision oncology, TEAM-D enables virtual case discussion across the different sectors of the German healthcare system. Based on the example of PIK3CA hotspot mutations, TEAM-D demonstrated the value of integrating knowledge from different healthcare professionals. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results